1. Hepatocyte-Specific Ablation or Whole-Body Inhibition of Xanthine Oxidoreductase in Mice Corrects Obesity-Induced Systemic Hyperuricemia Without Improving Metabolic Abnormalities
- Author
-
Michael J. Jurczak, Nikolas Dedousis, Eugenia Cifuentes-Pagano, Eckels Jt, Eric E. Kelley, Mandler Wk, Jianhai Du, Patrick J. Pagano, Robert M. O'Doherty, Maja Stefanovic-Racic, Brydie R. Huckestein, Daniel B. Harmon, Gregg E. Homanics, Van't Erve Tj, Yekai Wang, Ian Sipula, and Sara E. Lewis
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Xanthine Dehydrogenase ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Type 2 diabetes ,Hyperuricemia ,Carbohydrate metabolism ,Fatty Acids, Nonesterified ,Diet, High-Fat ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,Insulin resistance ,Febuxostat ,Internal medicine ,Internal Medicine ,medicine ,Animals ,Obesity ,Triglycerides ,Glucose tolerance test ,medicine.diagnostic_test ,business.industry ,Glucose Tolerance Test ,medicine.disease ,Lipid Metabolism ,Uric Acid ,030104 developmental biology ,Endocrinology ,Glucose ,chemistry ,Hepatocytes ,Uric acid ,business ,Dyslipidemia ,Obesity Studies ,medicine.drug - Abstract
Systemic hyperuricemia (HyUA) in obesity/type 2 diabetes facilitated by elevated activity of xanthine oxidoreductase (XOR), which is the sole source of uric acid (UA) in mammals, has been proposed to contribute to the pathogenesis of insulin resistance/dyslipidemia in obesity. Here, the effects of hepatocyte-specific ablation of Xdh, the gene encoding XOR (HXO), and whole-body pharmacologic inhibition of XOR (febuxostat) on obesity-induced insulin resistance/dyslipidemia were assessed. Deletion of hepatocyte Xdh substantially lowered liver and plasma UA concentration. When exposed to an obesogenic diet, HXO and control floxed (FLX) mice became equally obese, but systemic HyUA was absent in HXO mice. Despite this, obese HXO mice became as insulin resistant and dyslipidemic as obese FLX mice. Similarly, febuxostat dramatically lowered plasma and tissue UA and XOR activity in obese wild-type mice without altering obesity-associated insulin resistance/dyslipidemia. These data demonstrate that hepatocyte XOR activity is a critical determinant of systemic UA homeostasis, that deletion of hepatocyte Xdh is sufficient to prevent systemic HyUA of obesity, and that neither prevention nor correction of HyUA improves insulin resistance/dyslipidemia in obesity. Thus, systemic HyUA, although clearly a biomarker of the metabolic abnormalities of obesity, does not appear to be causative.
- Published
- 2018